Anticancer effects of 15d-prostaglandin-J 2 in wild-type and doxorubicin-resistant ovarian cancer cells: Novel actions on SIRT1 and HDAC

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  de Jong, Edwin ^a   Winkel, Peter ^a   Poelstra, Klaas ^a,b   Prakash, Jai ^a,b,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 9,10 DIHYDRO 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CASPASE 3; CASPASE 7; CAY 10410; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; SIRTUIN 1; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE; PROTEIN BCL X; SIRT1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ELONGATION; CELL MIGRATION; CELL SHAPE; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CARCINOMA; WILD TYPE; WOUND HEALING; CHEMISTRY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NF-KAPPA B; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROSTAGLANDIN D2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIRTUIN 1; STRUCTURE-ACTIVITY RELATIONSHIP; WOUND HEALING;

EID: 80052990769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025192     Document Type: Article

References (23)

1. Smith WL, (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263: F181-F191.
2. Itoh K, Mochizuki M, Ishii Y, Ishii T, Shibata T, et al. (2004) Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol Cell Biol 24: 36-45.
3. Staels B, Koenig W, Habib A, Merval R, Lebret M, et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793.
4. Prakash J, Bansal R, Post E, de Jager-Krikken A, de Hooge MH, et al. (2009) Albumin-binding and tumor vasculature determine the anti-tumor effect of 15-deoxy-delta12,14-Prostaglandin J2 in vivo. Neoplasia 11: 1348-1358.
5. Koyama M, Izutani Y, Goda AE, Matsui TA, Horinaka M, et al. (2010) Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res 16: 2320-2332.
6. Shin SW, Seo CY, Han H, Han JY, Jeong JS, et al. (2009) 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 15: 5414-5425.
7. Cho WH, Choi CH, Park JY, Kang SK, Kim YK, (2006) 15-deoxy-(Delta12,14)-prostaglandin J2 (15d-PGJ2) induces cell death through caspase-independent mechanism in A172 human glioma cells. Neurochem Res 31: 1247-1254.
8. Straus DS, Pascual G, Li M, Welch JS, Ricote M, et al. (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 97: 4844-4849.
9. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr, (1999) NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19: 5923-5929.
10. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A, (2005) Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65: 10183-10187.
11. Kim EH, Surh YJ, (2006) 15-deoxy-Delta12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors. Biochem Pharmacol 72: 1516-1528.
12. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, et al. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668.
13. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, et al. (2002) Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1: 1181-1190.
14. Broxterman HJ, Gotink KJ, Verheul HM, (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12: 114-126.
15. Eucker J, Sterz J, Krebbel H, Zavrski I, Kaiser M, et al. (2006) Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anticancer Drugs 17: 763-769.
16. Richardson A, Kaye SB, (2005) Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 8: 311-321.
17. tires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, et al. (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97.
18. Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, et al. (2003) NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278: 21631-21638.
19. Liu T, Liu PY, Marshall GM, (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69: 1702-1705.
20. Han L, Zhou R, Niu J, McNutt MA, Wang P, et al. (2010) SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res 38: 7458-7471.
21. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380.
22. Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, et al. (2008) The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 98: 489-495.
23. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, et al. (2005) Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103: 1631-1643.